# US 2016/0355479 A1 · Sulfonamide compounds and uses as tnap inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355479 A1
- Document ID: US20160355479A1
- Status: Published application
- Kind: A1
- Application number: 15/241,905
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2012-02-22
- Assignees: Sanford-Burnham Medical Research Institute
- Applicants: Sanford-Burnham Medical Research Institute
- Inventors: Anthony B. PINKERTON; Russell DAHL; Nicholas D.P. COSFORD; Jose Luis MILLAN
- Web page: https://patentgrep.com/patent/US20160355479A1

## CPC

- C07D 213/76: to which a second hetero atom is attached (nitro radicals C07D213/61)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- C07D 213/79: Acids; Esters
- C07D 213/80: in position 3
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 231/42: Benzene-sulfonamido pyrazoles
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 239/69: Benzenesulfonamido-pyrimidines
- C07D 241/22: Benzenesulfonamido pyrazines
- C07D 261/16: Benzene-sulfonamido isoxazoles
- C07D 263/50: Benzene-sulfonamido oxazoles
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 277/52: to sulfur atoms, e.g. sulfonamides
- C07D 285/135: Nitrogen atoms
- C07D 333/36: Nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, metabolite, or N-oxide thereof:
wherein:
Y1 and Y2 are independently a bond or —N(R6)—, wherein at least one of Y1 and Y2 is —N(R6)—;
L1 and L2 are independently a bond or optionally substituted alkylene;
X1 is ═N— or ═C(R2)—;
X2 is ═N— or ═C(R3)—;
R1 and R4 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R2, R3, and R5 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R6 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
R7 and R8 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted phenyl, or R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino;
R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
A is selected from the group consisting of —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
Y1 is a bond and Y2 is —N(R6)— as shown in Formula Ia:

### Claim 3 (depends on 1, 2)

The compound of any one of claims 1-2, wherein:
Y1 is a bond and Y2 is —N(R6)—; and
X2 is ═C(R3)— as shown in Formula Ib:

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein:
Y1 is a bond and Y2 is —N(R6)—;
X2 is ═C(R3)—; and
L1 is a bond as shown in Formula Ic.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein:
Y1 is a bond and Y2 is —N(R6)—;
X2 is ═C(R3)—;
L1 is a bond; and
L2 is a bond as shown in Formula Id:

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein:
Y1 is a bond and Y2 is —N(R6)—;
X2 is ═C(R3)—;
L1 is a bond;
L2 is a bond; and
R6 is hydrogen as shown in Formula Ie:

### Claim 7 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein L2 is an optionally substituted alkylene.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein X1 is ═C(R2)—.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R2, R3, and R5 are independently selected from the group consisting of hydrogen, —F, —Cl, —Br, —CN, —C(O)—OMe, methyl, —OMe, and —OCF3.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R2, R3, and R5 are independently selected from the group consisting of hydrogen, Cl, methyl, and —OMe.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R2 and R3 are hydrogen.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein Wand R4 are independently selected from the group consisting of hydrogen, —F, —Cl, —Br, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, methyl, —OMe, —OCF3, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R4 is optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R4 is —C(O)—N(R7)—R8, —C(O)—O—R9.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R1 and R4 are independently selected from the group consisting of —F, —Cl, —Br, —CN, —OMe, and —OCF3.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, wherein R1 is —OMe or —OCF3.

### Claim 17 (depends on 16)

The compound of claim 16, wherein R1 is —OMe and R4 is —Cl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17, wherein A is optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein A is selected from:
wherein:
R12 and R13 are independently selected from the group consisting of hydrogen, halogen, —CN, —OH, —C(O)—N(R17)—R18, —C(O)—O—R19, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl,
wherein:
R17 and R18 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted phenyl, or R17 and R18 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino; and
R19 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
R15 is hydrogen or optionally substituted alkyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein:
A is
wherein R12 and R13 are independently selected from the group consisting of hydrogen, —F, —CN, —OH, —OMe, and —C(O)—O-Me.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein A is —C(O)—O—R9.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R9 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted phenyl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R9 is selected from hydrogen, methyl, ethyl, propyl, cyclohexyl, and phenyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein A is —C(O)—N(R7)—R8.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino.

### Claim 26 (depends on 25)

The compound of claim 25, wherein the optionally substituted heterocycloamino is an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted morpholine, or an optionally substituted piperazine.

### Claim 27 (depends on 24)

The compound of claim 24, wherein R7 is hydrogen and R8 is optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted phenyl.

### Claim 28 (depends on 27)

The compound of claim 27, wherein R7 is hydrogen and R8 is selected from methyl, ethyl, propyl, 2-dimethylaminoethyl, 2-methoxyethyl, cyclohexyl, and phenyl.

### Claim 29 (depends on 24)

The compound of claim 24, wherein R7 and R8 are hydrogen.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition comprising a compound of any one of claims 1-29, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 31 (depends on 30)

A method of treating a disease in a subject mediated by tissue-nonspecific alkaline phosphatase (TNAP), which method comprises administering to the subject a pharmaceutical composition of claim 30.

### Claim 32 (depends on 31)

The method of claim 31, wherein the disease is a vascular calcification, ectopic ossification in spinal ligaments, ankylosis, or osteoarthritis.

### Claim 33 (depends on 32)

The method of claim 32, wherein the vascular calcification is an arterial calcification.

### Claim 34 (depends on 32)

The method of claim 32, wherein the vascular calcification is associated with diabetes mellitus I, diabetes mellitus II, idiopathic infantile arterial calcification (IIAC), Kawasaki disease, obesity, or increased age.

### Claim 35 (depends on 32)

The method of claim 32, wherein the vascular calcification is associated with chronic renal disease (chronic renal insufficiency), end-stage renal disease, or pre- or post-dialysis or uremia.

### Claim 36 (depends on 31)

The method of claim 31, wherein the disease is a pathological calcification.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pathological calcification is ankylosing spondylitis, tumoral calcinosis, fibrodysplasia ossificans progressiva, progressive osseous heteroplasia, pseudoxanthoma elasticum, ankylosis, osteoarthritis, general arterial calcification in infancy (GACI), arterial calcification due to deficiency of CD73 (ACDC), Keutel syndrome, peritoneal calcification, heterotopic calcification in amputees, tibial artery calcification, bone metastasis, prosthetic calcification, or Paget's disease of bone.
